MGRX Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
67.9K
-28.1%
94.4K
+12.0%
84.2K
-49.9%
168.1K
+53.8%
109.3K
Cost of Revenue
8.2K
-82.5%
46.9K
+40.6%
33.3K
-57.3%
78.2K
+216.0%
24.7K
Gross Profit
59.6K
+25.6%
47.5K
-6.7%
50.9K
-43.4%
89.9K
+6.4%
84.6K
Operating Expenses
1.8M
+9.1%
1.7M
-78.1%
7.6M
+41.7%
5.4M
+37.7%
3.9M
R&D
SG&A
1.5M
-86.6%
11.2M
+1066.2%
958.7K
-81.7%
5.3M
+141.6%
2.2M
Operating Income
-1755320
-8.6%
-1616002
+78.6%
-7542926
-43.2%
-5268495
-38.4%
-3807710
EBITDA
-1463732
-40.4%
-1042229
+86.1%
-7518098
-69.6%
-4432261
-30.6%
-3392718
Net Income
-3403141
-22.9%
-2769370
+63.7%
-7618776
-40.7%
-5415820
-11.9%
-4839489
EPS (Basic)
$-0.22
-4.8%
$-0.21
+69.6%
$-0.69
-21.1%
$-0.57
+49.1%
$-1.12
EPS (Diluted)
$-0.22
-4.8%
$-0.21
+69.6%
$-0.69
-21.1%
$-0.57
+49.1%
$-1.12
Shares (Diluted)
16.5M
+12.4%
14.7M
+27.3%
11.5M
+21.3%
9.5M
+106.9%
4.6M
Mangoceuticals (MGRX) — Financials